Melanoblast transcriptome analysis reveals novel pathways promoting melanoma metastasis

Kerrie L. Marie,Antonella Sassano,Howard H. Yang,Aleksandra M. Michalowski,Helen T. Michael,Theresa Guo,Yien Che Tsai,Allan M. Weissman,Maxwell P. Lee,Lisa M. Jenkins,M. Raza Zaidi,Eva Pérez-Guijarro,Chi-Ping Day,Heinz Arnheiter,Sean Davis,Paul S. Meltzer,Glenn Merlino,Pravin J. Mishra

DOI: https://doi.org/10.1101/721712

2019-08-06

Abstract:Abstract Cutaneous malignant melanoma is an aggressive cancer of melanocytes with a strong propensity to metastasize. We posited that melanoma cells acquire metastatic capability by adopting an embryonic-like phenotype, and that a lineage approach would uncover novel metastatic melanoma biology. We used a genetically engineered mouse model to generate a rich melanoblast transcriptome dataset, identified melanoblast-specific genes whose expression contributed to metastatic competence, and derived a 43-gene signature that predicted patient survival. We identified a melanoblast gene, KDELR3 , whose loss impaired experimental metastasis. In contrast, KDELR1 deficiency enhanced metastasis, providing the first example of different disease etiologies within the KDELR-family of retrograde transporters. We show that KDELR3 regulates the metastasis suppressor, KAI1, and report an interaction with the E3 ubiquitin-protein ligase gp78, a regulator of KAI1 degradation. Our work demonstrates that the melanoblast transcriptome can be mined to uncover novel targetable pathways for melanoma therapy.